ICON Public (NASDAQ:ICLR) Issues FY25 Earnings Guidance

ICON Public (NASDAQ:ICLR - Get Free Report) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $13.00-15.00 for the period, compared to the consensus earnings per share estimate of $14.86. The company issued revenue guidance of $8.05-8.65 billion, compared to the consensus revenue estimate of $8.50 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.

ICON Public Stock Down 8.1 %

Shares of ICON Public stock traded down $17.75 during trading hours on Tuesday, hitting $200.24. 1,830,683 shares of the company's stock traded hands, compared to its average volume of 899,485. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The stock has a 50 day simple moving average of $211.31 and a 200-day simple moving average of $270.81. The company has a market cap of $16.52 billion, a PE ratio of 22.32, a PEG ratio of 1.54 and a beta of 1.20.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analysts' expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. ICON Public's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 earnings per share. Equities research analysts anticipate that ICON Public will post 13.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ICLR shares. Leerink Partnrs upgraded shares of ICON Public to a "strong-buy" rating in a research note on Wednesday, September 18th. Leerink Partners reaffirmed an "outperform" rating and set a $255.00 price target (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Truist Financial reissued a "buy" rating and issued a $284.00 price objective (down from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. Redburn Atlantic started coverage on ICON Public in a report on Monday, October 14th. They set a "neutral" rating and a $311.00 target price on the stock. Finally, The Goldman Sachs Group decreased their target price on ICON Public from $370.00 to $280.00 and set a "buy" rating for the company in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $287.00.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.